HF
CLGN icon

HRT Financial’s CollPlant Biotechnologies CLGN Stock Holding History

HRT Financial’s Portfolio CLGN Stock Details CLGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-13,531
Closed -$221K – 3189
2021
Q4 		$221K Buy
+13,531
New +$241K ﹤0.01% 2470

Other funds holding CLGN

RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
IMOV
Investment Management of Virginia Richmond, Virginia $526M AUM 3.23% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
BFEC
Benjamin F. Edwards & Company St. Louis, Missouri $5.69B AUM 15.37% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HRT Financial's CLGN Position: Q1 2022 in Review

HRT Financial sold out of CollPlant Biotechnologies (CLGN) in Q1 2022, closing a stake of 13,531 shares — an estimated $221K sold.

HRT Financial first reported a position in CLGN in Q4 2021 and held it in 1 quarter. The position peaked at $221K in Q4 2021. 16 funds tracked by Wall St. Rank hold CLGN as of Q1 2022.

  • HRT Financial reported no remaining CollPlant Biotechnologies position as of Q1 2022 after selling out during the quarter.
  • HRT Financial sold 13,531 CollPlant Biotechnologies shares in Q1 2022, an estimated $221K.
  • HRT Financial first reported a position in CollPlant Biotechnologies in Q4 2021 and held it in 1 quarter.
  • HRT Financial's CollPlant Biotechnologies position peaked at $221K in Q4 2021.
  • 16 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q1 2022.

Based on HRT Financial's 13F filing for Q1 2022, filed 16 May 2022.